3 days 5 hours 55 minutes ago - GlobeNewswire via

New Post Public Reply Private Reply Replies (0) Message Board
ronb

3 days 5 hours 55 minutes ago - GlobeNewswire via Comtex

NIH Studies in New England Journal of Medicine Favor Chromosomal Microarray Analysis Over Standard Karyotyping for Genetic Analysis

CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that a pair of studies published in a leading journal favor chromosomal microarray analysis (CMA) over traditional karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirths. The two large studies, published in the current edition of the New England Journal of Medicine, represent the largest head-to-head studies comparing CMA to traditional karyotyping. Both concluded that CMA identified additional, clinically significant genetic abnormalities compared to karyotyping in both the prenatal diagnostic setting as well as the evaluation of stillbirths.

Ronald Wapner, M.D., one of the nation's leading clinicians in the field of reproductive genetics and the lead author of the prenatal diagnosis study and a co-author on the stillbirth study, has called for CMA to replace karyotyping, which has been the traditional standard of care for these tests. Wapner is the Director of Reproductive Genetics at New York Presbyterian Hospital/Columbia University Medical Center, and the Vice Chairman of Research and Professor of Obstetrics and Gynecology at Columbia College of Physicians and Surgeons.

While Wapner noted that the transition to CMA from karyotyping in clinical practice will be gradual, as physicians and patients continue to be educated about its use, the two studies make the choice clear: "Why would anyone want to continue to use the standard method, which gives only part of the answer?" Dr. Wapner said in a statement published earlier this year by the New York Presbyterian and Columbia University Medical Center.

The larger of the two studies, entitled "Chromosomal Microarray Versus Karyotyping for Prenatal Diagnosis," enrolled 4,406 women. In 4,340 (98.8 percent) of the fetal samples, microarray analysis was successful. The second study, entitled "Karyotype Versus Microarray Testing for Genetic Abnormalities After Stillbirth," 532 stillbirths were analyzed. That study concluded that "microarray analysis is more likely than karyotype analysis to provide a genetic diagnosis, primarily because of its success with nonviable tissue, and is especially valuable in analyses of stillbirths with congenital anomalies…"

Both studies were funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development--part of the National Institutes of Health (NIH).

R. Judd Jessup, President and CEO of CombiMatrix, the only publicly-traded company that specializes in CMA, noted that the studies showed conclusively the value of microarray testing. "The CMA test could eventually give parents, physicians and educators better tools for anticipatory care by proactively addressing the impacts of many chromosomal disorders," Jessup said.

In the case of stillbirths or miscarriages, especially when it happens more than once, "CMA can be used to determine if there is a genetic reason for these occurrences, and can give parents valuable information about future pregnancies," says Jessup.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory which offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was also the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," "objective," similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding the advantages and efficacy of CMA over standard karyotyping. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: market acceptance of CMA as a preferred method over karyotyping; the rate of transition to CMA from karyotyping; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in both developmental medicine and oncology; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: CombiMatrix Corporation

CONTACT: Company Contact:
R. Judd Jessup
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Investor Relations Contact:
John Baldissera
BPC Financial Marketing
Tel (800) 368-1217
Media Contact:
Len Hall
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
len@allencaron.com

CombiMatrix Corp (CBMX) Stock Research Links

CBMX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 38

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 301

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 23

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 5

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Comercial Português Adresses Legal Risks of FX Mortgages

Updated Category News Views 191

Understanding Legal Risks in FX Mortgage Loans Banco Comercial Português, S.A. is proactive in addressing estimated legal risks associated with the foreign exchange (FX) mortgage loans portfolio managed by Bank Millennium, S.A. This initiative reflects the bank's commitment to stability and customer security amidst a complex financial landscape. Estimated Provisions for...

Continue Reading
Elevating Dating: MillionaireMatch's New Travel Feature

Updated Category News Views 117

Introducing the New Feature on MillionaireMatch MillionaireMatch, the renowned dating website catering to billionaires and successful individuals, has launched an exciting new feature known as 'Willing to Fly to Meet.' This update empowers users to indicate their readiness to travel distances for a potential romantic connection. By opting into this feature, individuals...

Continue Reading
Whistle Design Sparks Innovation for Coaches and Trainers

Updated Category News Views 151

So, here’s the lowdown: a new whistle design is hitting the scene, aiming to make coaches’ calls clearer amidst the chaos of overlapping games. But let’s not get lost in the novelty—this isn’t just about some fancy gadget; it’s got implications worth dissecting. First up, this invention is supposedly patent-pending. That tag usually raises eyebrows in finance...

Continue Reading
UK Imposes Sanctions on Russian Military for Chemical Warfare

Updated Category News Views 119

UK Sanctions Against Russian Military Forces The UK government has taken a bold step to address the ongoing situation in Ukraine by imposing sanctions on Russian military personnel linked to the use of chemical weapons on the battlefield. This decisive action showcases the UK's commitment to upholding international law and protecting human rights. Targeted Sanctions on...

Continue Reading
PepsiCo Prepares for Challenging Q3 Amid Pricing Pressures

Updated Category News Views 296

PepsiCo's Current Market Position PepsiCo, Inc. (NASDAQ: PEP) continues to show resilience as it navigates a complex economic environment. Recently, the company’s shares have been trading slightly higher, reflecting a degree of investor confidence amidst ongoing market challenges. Analyst Insights on Upcoming Earnings According to analyst Peter T. Galbo from BofA...

Continue Reading